RecruitingNCT05092009
Lung Cancer Organoids and Patient Derived Tumor Xenografts
Sponsor
Maastricht Radiation Oncology
Enrollment
600 participants
Start Date
Oct 5, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- All patients selected to undergo primary surgical resection of a primary lung cancer. All types of resection are eligible, e.g. wedge resection, segmental resection, lobectomy, pneumonectomy.
- All patients with (suspected) lung cancer that will undergo a bronchoscopy or endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA) bronchoscopy.
Interventions
OTHERTissue and blood
Tissue and blood will be derived from patient during a standard of care procedure
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05092009
Related Trials
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
NCT066185991 location
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location
Empathic Communication Skills (ECS) Training
NCT0545684112 locations